Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...
Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...
Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...
Investing.com -- Gilead Sciences Inc (NASDAQ:GILD) stock rose 2.7% on Thursday after the company announced positive topline ...
Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval ...
PublicSource on MSN
Cuts in funds for HIV services threaten medication access, outreach
The Pennsylvania Department of Health will cut 25% of funding to the Part B of the Ryan White HIV/AIDS Program amid rising ...
Despite Uganda's steady progress in reducing HIV infections and AIDS-related deaths, men remain disproportionately affected due to low uptake of antiretroviral treatment (ARVs), the Uganda AIDS ...
A Thai man accused a gay man in the central province of Saraburi of spreading HIV within the LGBTQIA+ community and trading ...
Organizations that provide services like HIV education and living recommendations are being forced to cut programming after ...
Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
A Jacobs School of Medicine and Biomedical Sciences faculty member is senior author on a newly published study on the public health challenges of HIV in Nigeria.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback